Invited Commentary
Commentary on “Updated Prevalence and Demographic Characteristics for ALS Cases in Texas, 2009–2011”
Abstract
One of the most challenging and difficult diagnoses a neurologist can give a patient is that of amyotrophic lateral sclerosis (ALS). The implications of the diagnosis and the perception that little can be done to stop the relentless progression of the disease often lead to a great deal of uncertainty and a sense of hopelessness. Patients, their family and caregivers, and the physicians treating them often are pushed into discussing quality of life and end-of-life issues early in the course of the disease, which is a constant reminder of the inevitable demise of the patient.This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
References
1. Tiryaki E, Horak HA. ALS and other motor neuron diseases. Continuum (Minneap Minn) 2014;20:1185-1207.
2. Goutman SA, Feldman EL. Clinical trials of therapies for amyotrophic lateral sclerosis: one size does not fit all. JAMA Neurol 2015 May 11. [Epub ahead of print] .
3. Rechtman L, Wagner L, Kaye W, et al. Updated prevalence and demographic characteristics for ALS cases in Texas, 2009Y2011. South Med J 2015;108:483-486.
4. Feigin VL, Howard G. The importance of epidemiological studies should not be downplayed. Stroke 2008;39:1-2.
5. Croin S, Hardiman O, Traynor BJ. Ethnic variation in the incidence of ALS: a systematic review. Neurology 2007;68:1002-1007.
